Persephone Biosciences Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6.3M
- Investors
-
29
Persephone Biosciences General Information
Description
Developer of equitable precision medicines designed to focus on microbial therapeutics for immuno-oncology applications. The company's medicines use artificial intelligence and omics techniques on multiple cancer patient gut microbiomes and blood samples to identify microbes needed for normal immune function for population-scale patient data analytics, enabling lab researchers to design microbial drugs that prevent and fight cancer.
Contact Information
Website
www.persephone.bioCorporate Office
- 10835 Road to the Cure
- Suite 150
- San Diego, CA 92121
- United States
Corporate Office
- 10835 Road to the Cure
- Suite 150
- San Diego, CA 92121
- United States
Persephone Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 11-Oct-2024 | $6.3M | Completed | Generating Revenue | ||
| 5. Secondary Transaction - Private | 01-Oct-2022 | Completed | Generating Revenue | |||
| 4. Seed Round | 13-Jul-2022 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 08-Jan-2018 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 17-Jul-2017 | $200K | $200K | Completed | Startup | |
| 1. Accelerator/Incubator | 17-Jul-2017 | Completed | Startup |
Persephone Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 1,044,676 | $0.000100 | $0.02 | $0.22 | $0.22 | 1x | $0.22 | 2.46% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Persephone Biosciences Comparisons
Industry
Financing
Details
Persephone Biosciences Competitors (3)
One of Persephone Biosciences’s 3 competitors is Eligo Bioscience, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Eligo Bioscience | Venture Capital-Backed | Paris, France | ||||
| Second Genome | Formerly VC-backed | Brisbane, CA | ||||
| MatriSys Bioscience | Venture Capital-Backed | San Diego, CA |
Persephone Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Persephone Biosciences Patents
Persephone Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025264805-A3 | Synbiotics for modulating gut microflora populations | Pending | 21-Jun-2024 | ||
| WO-2025264805-A2 | Synbiotics for modulating gut microflora populations, treatment of dysbiosis and disease prevention, and methods for making and using same | Pending | 21-Jun-2024 | ||
| AU-2024230804-A1 | Compositions for modulating gut microflora populations, treatment of dysbiosis and disease prevention, and methods for making and using same | Pending | 28-Feb-2023 | ||
| EP-4673157-A2 | Compositions for modulating gut microflora populations, treatment of dysbiosis and disease prevention, and methods for making and using same | Pending | 28-Feb-2023 | ||
| US-20260231998-A1 | Compositions for modulating gut microflora populations, treatment of dysbiosis and disease prevention, and methods for making and using same | Pending | 28-Feb-2023 | A23L33/135 |
Persephone Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Persephone Biosciences Investors (29)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Capita3 | Venture Capital | Minority | ||
| Exitfund | Venture Capital | Minority | ||
| Gaingels | Venture Capital | Minority | ||
| Mesa Verde Venture Partners | Venture Capital | Minority | ||
| Ocampo Capital | Venture Capital | Minority |
Persephone Biosciences FAQs
-
When was Persephone Biosciences founded?
Persephone Biosciences was founded in 2017.
-
Where is Persephone Biosciences headquartered?
Persephone Biosciences is headquartered in San Diego, CA.
-
What is the size of Persephone Biosciences?
Persephone Biosciences has 19 total employees.
-
What industry is Persephone Biosciences in?
Persephone Biosciences’s primary industry is Drug Discovery.
-
Is Persephone Biosciences a private or public company?
Persephone Biosciences is a Private company.
-
What is the current valuation of Persephone Biosciences?
The current valuation of Persephone Biosciences is .
-
What is Persephone Biosciences’s current revenue?
The current revenue for Persephone Biosciences is .
-
How much funding has Persephone Biosciences raised over time?
Persephone Biosciences has raised $21.6M.
-
Who are Persephone Biosciences’s investors?
Capita3, Exitfund, Gaingels, Mesa Verde Venture Partners, and Ocampo Capital are 5 of 29 investors who have invested in Persephone Biosciences.
-
Who are Persephone Biosciences’s competitors?
Eligo Bioscience, Second Genome, and MatriSys Bioscience are competitors of Persephone Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
